The Psychotropic Drug Intervention Program, or PDIP, is a unique and comprehensive quality management program that focuses on identifying claims-based, medication-related problems through the use of analytics and clinical review. Using innovative technologies, the program engages both prescribers and members to understand and resolve medication related issues. It is designed to be complementary to the traditional services offered by pharmacy benefit management and is customized to the needs of the client.
IDENTIFYING PROBLEMS
Employing evidenced-based medicine algorithms to identify suspected
medication-related problems, PDIP’s offerings include:
- Monitoring medication adherence for members taking psychotropic medications that require consistent, ongoing use
- Identifying sub-therapeutic, geriatric dosing of psychotropic medications that require therapeutic dosing
- Identifying poly-pharmacy of psychotropic medications
- Recognizing potential cases of uncoordinated care and prescribing by multiple clinicians treating the same member
- Checking for possible fraudulent or abusive prescriptive patterns
- Monitoring for outlier member cases when there are potential medication utilization safety concerns
IMPROVING OUTCOMES AND CONTROLLING COSTS
PDIP’s innovative products provide the analytical surveillance necessary to understand complex medication utilization patterns and provide management strategies necessary to ensure appropriate and safe medication use. These programs result in cost reduction, improvement in health outcomes and when applicable, improved HEDIS scores.
PROGRAM OUTCOMES
Outcomes to date have been impressive, delivering a 15 percent return on investment to our health plan customers in year one of operation. In addition, quality metrics have improved markedly, including:
- 29% positive change in the medication possession ratio
- 74% positive change in sub-optimal dosing
- 20% reduction in the incidence of non-evidence based polypharmacy, primarily resulting from the elimination of uncoordinated care